<div id="readability-page-1"><div><ul> <li>Agilent Technologies has recently completed a leadership transition, appointing Michael Buckner as Chief Legal Officer after Bret DiMarco resigned and moved into a Special Advisor role to support the handover.</li> <li>This change puts an experienced legal executive at the center of Agilent’s regulatory, M&amp;A, and governance agenda, with potential implications for risk management and corporate decision‑making.</li> <li>Next, we’ll explore how Buckner’s appointment as Chief Legal Officer could influence Agilent’s existing investment narrative around growth, margins, and resilience.</li> </ul><p>Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.</p><h2>Agilent Technologies Investment Narrative Recap</h2><p>To own Agilent, you need to believe in its role as a core tools provider across life sciences, diagnostics, and applied chemicals, supported by steady earnings and disciplined capital returns. The appointment of Michael Buckner as Chief Legal Officer does not materially change the near term focus on new diagnostic approvals and ongoing buybacks as key supports, nor does it directly alter the primary risk around tariff driven cost pressure and supply chain complexity.</p> <p>Among recent announcements, the FDA approval for Agilent’s PD L1 IHC 22C3 pharmDx as a companion diagnostic for multiple KEYTRUDA indications looks most relevant, because it reinforces the company’s diagnostics pipeline at a time when investors are watching for product driven growth catalysts to offset end market funding pressures and tariff related margin headwinds.</p> <p>Yet beneath this seemingly straightforward story, rising tariff driven costs and supply chain complexity could create pressures that investors should be aware of if...</p> <p>Read the full narrative on Agilent Technologies (it's free!)</p><p>Agilent Technologies' narrative projects $8.6 billion revenue and $2.0 billion earnings by 2029. This requires 6.7% yearly revenue growth and a roughly $0.7 billion earnings increase from $1.3 billion today.</p><p>Uncover how Agilent Technologies' forecasts yield a $160.69 fair value, a 43% upside to its current price.</p><h2>Exploring Other Perspectives</h2><figure><img height="476" src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/69975872-a59c-46dc-9697-192d6a3dc958/chart/quote-price?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="746" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/69975872-a59c-46dc-9697-192d6a3dc958/chart/quote-price"/><figcaption>A 1-Year Stock Price Chart</figcaption></figure> <p>Five Simply Wall St Community valuations span roughly US$125 to US$161 per share, underscoring how far apart individual views on Agilent’s worth can be. You can set those opinions against the tariff and supply chain risks discussed earlier to weigh how resilient the company’s earnings profile might prove over time.</p><p>Explore 5 other fair value estimates on Agilent Technologies - why the stock might be worth just $125.18!</p><h2>Reach Your Own Conclusion</h2><p>Don't just follow the ticker - dig into the data and build a conviction that's truly your own.</p><ul><li>A great starting point for your Agilent Technologies research is our analysis highlighting 4 key rewards that could impact your investment decision.</li><li>Our free Agilent Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Agilent Technologies' overall financial health at a glance.</li></ul><h2>Ready For A Different Approach?</h2><p>Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:</p><ul><li>Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.</li><li>Uncover the next big thing with 21 elite penny stocks that balance risk and reward.</li><li>Find 48 companies with promising cash flow potential yet trading below their fair value.</li></ul> <p><em> This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data     and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your     financial situation. We aim to bring you long-term focused analysis driven by fundamental data.     Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.     Simply Wall St has no position in any stocks mentioned.</em></p><div><h3><strong>New: </strong>Manage All Your Stock Portfolios in One Place</h3><p>We've created the <strong>ultimate portfolio companion</strong> for stock investors, <strong>and it's free.</strong></p><p>• Connect an unlimited number of Portfolios and see your total in one currency<br/>• Be alerted to new Warning Signs or Risks via email or mobile<br/>• Track the Fair Value of your stocks<br/></p><p>Try a Demo Portfolio for Free</p></div></div></div>

LABU

<p>Agilent Technologies has appointed Michael Buckner as Chief Legal Officer, succeeding Bret DiMarco. This leadership change may impact Agilent's regulatory and governance strategies, particularly in risk management and corporate decision-making. Despite this transition, Agilent's focus on diagnostic approvals and buybacks remains unchanged. The company projects $8.6 billion in revenue and $2.0 billion in earnings by 2029, with a fair value estimate of $160.69, indicating a 43% upside from its current price. Investors should consider tariff and supply chain risks when evaluating Agilent's earnings resilience.</p>

Simplywall

Agilent Tech

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

iShares US Medical Devices

VanEck Biotech ETF

ALPS Medical Breakthrough

SPDR S&P Health Equip

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Does Agilent’s New Chief Legal Officer Shift the Risk‑Reward Balance in Its Strategy (A)?